AMRA Medical and UK Biobank data provides evidence to predict the occurrence of disease
LINKÖPING, Sweden; May 16, 2019 – A new publication in Obesity journal dated May 16, 2019, contains groundbreaking data from AMRA Medical on its ability to predict the occurrence of disease in individual patients based on real-world evidence from the UK Biobank. Individualized data can be used to create virtual control groups and deeply enrich the patient populations selected in a clinical trial.
AMRA utilized medical data from 10,019 participants in the UK Biobank imaging sub-study. Advanced imaging analysis techniques were applied to the magnetic resonance imaging (MRI) data and body composition profiles, containing visceral and abdominal subcutaneous adipose tissue, muscle fat infiltration, and liver fat were analyzed for each participant. Algorithms were applied to calculate individualized Coronary Heart Disease (CHD) and Type 2 Diabetes (T2D) propensities, or natural inclination, towards these diseases. In addition, the research explored how, in the clinically relevant areas of obesity and non-alcoholic fatty liver disease (NAFLD), metabolic disease phenotypes can be identified to describe an individual’s inclination towards CHD and T2D.
AMRA Medical’s CEO, Eric Converse, sees virtual control groups and sub-phenotyping as key milestones for clinical trial optimization and the company’s precision medicine growth:
“Individualized phenotyping and disease prediction are the Holy Grail in medicine. A person’s body weight, waist circumference and general appearance may seem ideal. However, our research shows that AMRA analytics taken from a simple MRI scan tells you so much more about what’s going on inside the body and what disease propensities may be lurking. Quite simply – ‘don’t judge a body by its cover.’”
UK Biobank’s Principal Investigator, Professor Rory Collins agrees:
“UK Biobank’s success has allowed us to ask a lot more of our half a million volunteer participants – including inviting them to have full body scans. We have scanned almost 40,000 people and aim for 100,000. It is clear that these pictures are providing incredibly important information to a wide range of scientists who are getting on with the business of improving health. This new work, linking fat distribution and heart health, is based on just 10,000 images. Imagine the power of ten times that number of scans, which we will have in a few years’ time, to improve diagnosis and treatment of disease. We are very grateful to our participants for giving up their time to help create this exciting resource.”
Read the online publication in Obesity:
About AMRA Medical
AMRA is a groundbreaking international digital health company at the forefront of medical imaging and precision medicine. The company has developed a new global standard in body composition assessment, the ability to automatically produce multiple fat and muscle biomarkers with unrivaled precision and accuracy, as well as contextual disease insights – all from a single, Rapid MRI, whole-body MRI. AMRA was founded in 2010 as a spin-off of Linköping University, Sweden, with the aim to support transformative care and vital decision-making from clinical research to health and wellness.
SVP Global BD & Marketing
About UK Biobank
UK Biobank (www.ukbiobank.ac.uk) is a major national and international health resource with the aim of improving the prevention, diagnosis and treatment of a wide range of serious and life-threatening illnesses. In 2006-2010, UK Biobank recruited 500,000 people between the ages of 40–69 years old from across the country. The project has permission to follow participants’ health through medical records. UK Biobank has also embarked on a major project to MRI scan the vital internal organs and body composition of 100,000 participants. Over many years, these detailed data will build a powerful resource to help scientists discover why some people develop particular diseases and others do not, and to suggest new ways of preventing and treating them.
Head of Communications